$CMPX

Stifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.

Compass Therapeutics (CMPX) shares dropped 6% after FDA recommended additional trials for Tovecimig. Analysts cut price targets; H.C. Wainwright to $12, Wedbush to $1. Compass plans BLA submission in Q1 2027 despite FDA concerns. Stock down 76% YTD, trading at $1.2.

Stifel maintained a Buy rating and $6.00 price target for Compass Therapeutics (CMPX), citing positive regulatory feedback on tovecimig. The stock is down 81% from its 52-week high, trading at $1.31. The company plans a 2027 biologics license application and has a current ratio of 11.22, despite cash burn. Stifel noted undervaluation and upcoming catalysts.

Compass Therapeutics (CMPX) shares fell over 25% after the FDA recommended an additional trial for its cancer drug Tovecimig, potentially delaying its marketing application. The FDA wants a trial demonstrating improved overall survival in advanced biliary tract cancer patients. Compass disagrees and plans further discussions. The company has $180 million in cash, expected to last into 2028. CMPX shares traded at over 2-year lows.

Compass Therapeutics (CMPX) shares dropped 40.8% to $1.51 in premarket trading after the FDA recommended an additional trial for tovecimig, an experimental cancer treatment. The company disagrees and plans to continue discussions with the FDA.

Compass Therapeutics, Inc. (CMPX) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig. Compass does not believe that a new

Compass Therapeutics, Inc. (CMPX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with bilia

Compass Therapeutics, Inc. (CMPX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001738021 0001738021 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

This article provides access to a DEFA14A filing by Compass Therapeutics. These filings are preliminary proxy statements that include important information for shareholders prior to a definitive proxy statement.

Compass Therapeutics has released its full 2025 financial results, highlighting significant progress in its clinical-stage pipeline. The company reported $209 million in cash and marketable securities, providing a runway into 2028. Key updates include reaching the event threshold for its tovecimig study in biliary tract cancer, expanding cohorts for CTX-8371 in TNBC and NSCLC, and FDA clearance for CTX-10726, with Phase 1 studies commencing.